Israeli-American company ORAVAX MEDICAL is preparing to begin clinical trials in the world’s first oral vaccine against coronavirus. It is reported by Edition The Jerusalem POST.
According to the report, this company is a joint venture of the Israeli pharmaceutical company Oramed Pharmaceuticals and American Premas Biotech. Oramed develops the technology of oral administration of protein-based drugs. Premas works on creating a new type vaccine against coronavirus.
oral vaccine will be easier to store and transport – it does not require deep freezing. Theoretically, it is possible to take on their own, including at home. Easy administration can become particularly important if the coronavaccine becomes an annual, as a standard influenza vaccination.
Premas Biotech has already experienced its vaccine on animals and found that it contributes to the development of antibodies to immunoglobulin G (IgG) and immunoglobulin A (IgA). IGA antibodies are needed for long-term immunity.
“The ORAVAX vaccine is aimed at three structural protein of coronavirus, unlike one” spike “protein, which is aimed at the MODERNA and Pfizer vaccine. Due to this, it must be effective against different strains COVID-19” , – said CEO Oramed Nadav Kidron.
In addition, it is much lower than that of its already approved competitors.
ORAVAX plans to start clinical trials of its vaccine on people in the second quarter of 2021. The company applies for tests in many countries, including the United States, Israel, Europe and Mexico. The company is especially hoping for Africa, where simple in transportation, storage and reception of the vaccine may be a real rescue.